Anti-inflammatory compounds that target chronic inflammation pathways and support whole-body recovery.
31 itemsDoes cold exposure right after lifting blunt hypertrophy? Research suggests routine, immediate post-exercise cold may attenuate muscle growth, while still helping short-term recovery needs.
A focused, evidence-based review of L‑glutamine for exercise‑induced gut permeability in athletes, bridging modern research with traditional nutrition perspectives.
A focused look at how mushroom beta‑glucans engage Dectin‑1 and other receptors to modulate innate immunity, why extraction methods matter, and where human evidence stands.
Is zonulin testing a reliable way to assess intestinal permeability? This evidence-based review explains the science, assay controversies, and practical takeaways.
Can astragalus (Huang Qi) or TA-65 meaningfully support telomere health? A concise, evidence-based review of telomerase activation, human data, safety, and where traditional and modern perspectives meet.
A focused look at how caloric restriction and rapamycin converge on the mTOR pathway, what ITP mouse studies show, early human and dog trial signals, risks, and natural mTOR modulators.
A focused look at whether post‑workout cold exposure blunts muscle growth, summarizing trials, mechanisms, and where cold may still fit for short‑term recovery.
BPC-157 and tissue repair: what animal studies suggest about tendon and ligament healing, why athletes are curious, and the current gap in human clinical evidence and safety.
A focused, evidence-based look at turkey tail mushroom’s PSK/PSP beta-glucans, how they may modulate immunity, what clinical research suggests, why extraction matters, and how this aligns with TCM.
A focused, evidence-based guide to the lactulose–mannitol test for intestinal permeability: how it works, what an abnormal result may mean, key limitations, how it compares with zonulin assays, and what trials show about modulating the test.
Research-based look at when autophagy may start during fasting, what triggers it, and how time-restricted eating, alternate-day fasting, fasting-mimicking diets, and Ramadan relate to autophagy.
Resveratrol’s mixed human results may stem from low bioavailability and metabolite complexity. This focused review explains the sirtuin controversy, summarizes clinical evidence, and compares resveratrol with other polyphenols.
A focused review of what the NIA Interventions Testing Program (ITP) reveals about rapamycin’s lifespan effects, how it intersects with caloric restriction via mTOR, early dog and human data, risks, and natural modulators.
Research suggests immediate post-lift ice baths may blunt hypertrophy and strength gains. See what RCTs and reviews show, and when cold can still help recovery.
Animal research suggests BPC-157 may enhance tendon and ligament healing via angiogenesis and collagen remodeling, but human trials are lacking. Learn what the preclinical evidence shows, safety and regulatory considerations, and why athletes are interested.
A focused look at molecular mimicry—how gut microbes and infections may trigger autoimmunity—and what current evidence shows across conditions like T1D, RA, and thyroid autoimmunity.
A focused, evidence-based look at turkey tail mushroom’s PSK/PSP and immunity—mechanisms, clinical adjunct data, extraction methods, and how TCM perspectives align with modern research.
A focused, evidence-based review of bovine colostrum for intestinal permeability—what human trials show in NSAID and exercise stress, where evidence is stronger (infectious diarrhea) vs. still emerging, and how traditional perspectives align.
Resveratrol’s promise meets pharmacokinetics: how low bioavailability shapes human results, what sirtuin research really suggests, and which delivery strategies are emerging.
The ITP’s rapamycin results show strong lifespan extension in mice via mTORC1 inhibition. Here’s how that connects to caloric restriction, ongoing human and dog trials, risks, and natural mTOR modulators—and why excitement is tempered by caution.
Do cold plunges after lifting blunt muscle gains? Research on post-workout ice baths, DOMS, and training adaptations, plus contrast therapy and tradition.
BPC-157 shows promising tissue repair signals in animal studies, but no peer-reviewed human trials confirm benefits. Learn the mechanisms, safety gaps, and why athletes are interested—plus anti-doping status.
A focused, evidence-based explainer on molecular mimicry—how immune responses to gut microbes may cross-react with self and contribute to autoimmune disease.
A focused look at how mushroom beta‑glucans may modulate innate immunity and the gut‑immune axis, why extraction methods matter, and what clinical research suggests.
A rich source of EPA and DHA omega-3 fatty acids, commonly used to support cardiovascular health and reduce inflammation.
Omega-3 fatty acids — specifically EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) — are polyunsaturated fats that the human body cannot synthesize de novo. They must be obtained from dietary sources, primarily fatty fish (salmon, mackerel, sardines, anchovies), shellfish, and marine algae. EPA and DHA serve as structural components of cell membranes throughout the body, with particularly high concentrations in the brain (DHA comprises roughly 40% of polyunsaturated fatty acids in the brain) and retina. Beyond structural roles, they are precursors to specialized pro-resolving mediators (SPMs) — resolvins, protectins, and maresins — that actively resolve inflammation rather than simply suppressing it. The evidence base for omega-3 supplementation is extensive. Large-scale trials and meta-analyses support benefits for cardiovascular health (triglyceride reduction, modest blood pressure lowering), inflammatory conditions, mood disorders, and cognitive maintenance. The American Heart Association recommends at least two servings of fatty fish per week, and higher-dose EPA supplementation has been shown to reduce cardiovascular events in the REDUCE-IT trial.
A bright yellow spice derived from the Curcuma longa plant, widely used in Ayurvedic and traditional medicine for its anti-inflammatory properties.
Osteoarthritis (OA) is the most common arthritis, driven by age, mechanical loading, prior injury, obesity, and genetics. It features progressive cartilage loss, subchondral bone changes, synovial activation, and periarticular muscle weakness. Patients typically report activity-related joint pain, stiffness (often <30 minutes in the morning), reduced function, and sometimes swelling or crepitus. Knees, hips, hands, and spine are most affected. Diagnosis is clinical, supported by radiographs showing joint-space narrowing, osteophytes, and sclerosis; MRI is rarely required for routine care. Western management prioritizes nonpharmacologic strategies with the strongest, most consistent benefits across guidelines: education, exercise therapy (aerobic, strengthening, neuromuscular/balance), and weight reduction for those with overweight/obesity. Topical NSAIDs are recommended as first-line pharmacologic therapy for knee and hand OA, with oral NSAIDs used when needed and appropriate. Acetaminophen has diminishing evidence of benefit. Duloxetine can help chronic OA pain, particularly knee OA. Intra-articular corticosteroid injections offer short-term relief; hyaluronic acid remains controversial with mixed evidence. Platelet-rich plasma (PRP) injections are emerging but heterogeneous and not yet guideline-endorsed broadly. Joint replacement is highly effective for end-stage disease. Eastern and traditional approaches conceptualize OA differently but often converge on movement-based and symptom-relieving therapies. In Traditional Chinese Medicine (TCM), OA commonly maps to Bi syndrome (painful obstruction) with patterns such as wind-cold-damp Bi, blood stasis, and kidney (shen) deficiency. Treatment may include acupuncture (including electroacupuncture and warm-needle techniques), moxibustion, topical herbal liniments (e.g., capsicum), tuina/manual therapy, and herbal formulas (e.g., Du Huo Ji Sheng Tang). Acupuncture for knee OA is among the best-studied TCM applications,
Rheumatoid arthritis (RA) is a chronic, systemic, autoimmune synovitis that, without timely control, leads to pain, progressive joint damage, disability, and increased cardiovascular risk. Western medicine defines RA by characteristic clinical patterns, serologic autoantibodies, and inflammatory markers, and prioritizes early, aggressive disease modification using a treat‑to‑target strategy. This approach, guided by rigorous randomized trials and international guidelines, has transformed outcomes—many patients can now achieve low disease activity or remission and preserve function. Diagnosis in Western practice uses ACR/EULAR classification criteria that integrate joint involvement, rheumatoid factor (RF) and anti‑cyclic citrullinated peptide (anti‑CCP) antibodies, acute‑phase reactants (ESR/CRP), and symptom duration. Imaging (ultrasound/MRI) can detect subclinical synovitis and erosions early. Management begins promptly—ideally within weeks of symptom onset—because early window therapy improves long‑term trajectories. First‑line conventional synthetic disease‑modifying antirheumatic drugs (csDMARDs) include methotrexate (anchor), sulfasalazine, hydroxychloroquine, and leflunomide. If targets (remission/low disease activity) are not met, biologic DMARDs (e.g., TNF, IL‑6, T‑cell costimulation, anti‑CD20) or targeted synthetic JAK inhibitors are added or substituted, with iterative monitoring every 1–3 months and shared decision‑making. Short glucocorticoid courses are sometimes used as a bridge, while NSAIDs treat pain but do not alter disease course. Safety monitoring, vaccination, infection screening, and comorbidity risk reduction (e.g., cardiovascular prevention, bone health, smoking cessation, exercise, rehabilitation) are integral. Eastern and traditional systems conceptualize RA differently but share aims of reducing pain, swelling, and functional limitations while preventing chronic deterioration. Traditional Chinese Medicine (TCM) frames RA within “Bi” (B
Arthritis (an umbrella term that includes inflammatory types such as rheumatoid arthritis and non‑inflammatory types such as osteoarthritis) and osteoporosis frequently intersect in mid‑ to late‑li...
Psoriasis is a chronic, immune-mediated skin disease affecting roughly 2–3% of the population. Psoriatic arthritis (PsA) is an inflammatory arthropathy that occurs in a substantial subset of people...
